Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evogene Ltd.EVGN · Entity 8065 | Director | September 04, 2026 | September 30, 2026 |
| Innoviz Technologies Ltd.INVZ · Entity 6753 | Director | May 13, 2026 | May 15, 2026 |
| NICE Ltd.NICE · Entity 3764 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evogene Ltd.
Report date September 04, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.58 · Expires 2036-09-04 | Direct | 2,500 |
Reported balance
After 2026-09-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-04 · Grant · Acquired 2,500 · Balance 2,500 F1: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date. F2: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan. F3: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.51 · Expires 2032-09-15 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.03 · Expires 2033-05-11 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.16 · Expires 2034-06-13 | Direct | 1,800 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 1,800 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-08-18 | Direct | 2,500 |
Reported balance
Holding disclosure · report date 2026-09-04 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 2,500 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date.
F2: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan.
F3: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date.
F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Innoviz Technologies Ltd.
Report date May 13, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 344,997 |
Reported balance
After 2026-05-13 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 110,668 · Balance 344,997 F1: Represents 110,668 Restricted Share Units (RSUs) granted on May 13, 2026, which shall fully vest on April 5, 2027, subject to the Reporting Person remaining a service provider of the Issuer on the vesting date. Each RSU represents a contingent right to receive one ordinary share. No exercise price is applicable. F2: Includes 234,329 ordinary shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 110,668 Restricted Share Units (RSUs) granted on May 13, 2026, which shall fully vest on April 5, 2027, subject to the Reporting Person remaining a service provider of the Issuer on the vesting date. Each RSU represents a contingent right to receive one ordinary share. No exercise price is applicable.
F2: Includes 234,329 ordinary shares.
NICE Ltd.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 696 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Exercise / conversion · Acquired 696 · Balance 696 |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.29 · Expires 2026-09-10 | Direct | 0 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Exercise / conversion · Disposed 696 · Balance 0 F1: The stock option is fully vested and currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option is fully vested and currently exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 30, 2026 08:05 UTC | Evogene Ltd. EVGN · Entity 8065 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001178913-26-004658 · ownership.xml · derivative · entry 1 Falk Dan Michael · CIK 0001966097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 2,500 shares Expires 2036-09-04 F1 · derivative.exercise_price: The exercise price of the stock options to purchase Ordinary Shares of the Issuer (the "Options") is New Israeli Shekels ("NIS") 1.75 per share, which is equivalent to $0.58 per share based on the representative exchange rate of NIS 3.0050 per U.S. dollar published by the Bank of Israel on September 4, 2026, the grant date. F2 · kind: The transaction reported in this row consists of the grant by the Issuer's board of directors to the Reporting Person of 2,500 Options under the Issuer's 2021 Share Incentive Plan. F3 · derivative.exercise_date: The Options vest and become exercisable on a quarterly basis (25% per quarter) commencing on the grant date of September 4, 2026, such that they will be fully vested by September 4, 2027, the one-year anniversary of the grant date. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 10:00 UTC | NICE Ltd. NICE · Entity 3764 | Exercise / conversionOptions · Derivative | 696 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001178913-26-003089 · zk2635495.xml · derivative · entry 2 Falk Dan Michael · CIK 0001966097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 696 shares Expires 2026-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and currently exercisable. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 10:00 UTC | NICE Ltd. NICE · Entity 3764 | Exercise / conversionOrdinary Shares | 696 | $0.29 | $203.86 |
DisclosureSEC source: 0001178913-26-003089 · zk2635495.xml · nonDerivative · entry 1 Falk Dan Michael · CIK 0001966097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2026 Filed May 15, 2026 10:07 UTC | Innoviz Technologies Ltd. INVZ · Entity 6753 | GrantOrdinary Shares | 110,668 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-002715 · ownership.xml · nonDerivative · entry 1 Falk Dan Michael · CIK 0001966097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,997 F1 · shares: Represents 110,668 Restricted Share Units (RSUs) granted on May 13, 2026, which shall fully vest on April 5, 2027, subject to the Reporting Person remaining a service provider of the Issuer on the vesting date. Each RSU represents a contingent right to receive one ordinary share. No exercise price is applicable. F2 · balance_after: Includes 234,329 ordinary shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.